Pinned
1. Today the Federal Circuit rejected Teva's bid to list device patents for inhalers in the Orange Book.
Practically this means that drug makers can't list patents for things like inhaler caps to block generic rivals from the market & keep prices high.
A big win for Americans.
FTC Chair Lina Khan shows Lesley Stahl an asthma inhaler that costs dollars in Europe but hundreds in the U.S. She says drugmakers register patents on inhaler parts like the cap-strap to keep low-cost generics off the market. cbsn.ws/3zuONT2

00:00

















